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Background: Predictors of hospitalisation in people with HIV (PLHIV) in the contemporary treatment era are
not well understood.
Methods: This ASTRA sub-study used clinic data linkage and record review to determine occurrence of hospi-
talisations among 798 PLHIV from baseline questionnaire (February to December 2011) until 1 June 2018.
Associations of baseline social circumstance, socioeconomic, lifestyle, mental health, demographic and clini-
cal factors with repeated all-cause hospitalisation from longitudinal data were investigated using Prentice-
Williams-Peterson models. Associations were also assessed in 461 individuals on antiretroviral therapy
(ART) with viral load 50 copies/ml and CD4 count 500 cells/ml.
Findings: Rate of hospitalisation was 5.8/100 person-years (95% CI: 5.16.5). Adjusted for age, demographic
group and time with diagnosed HIV, the following social circumstance, socioeconomic, lifestyle and mental
health factors predicted hospitalisation: no stable partner (adjusted hazard ratio (aHR)=1.59; 95%
CI=1.162.20 vs living with partner); having children (aHR=1.50; 1.082.10); non-employment (aHR=1.56;
1.072.27 for unemployment; aHR=2.39; 1.703.37 for sick/disabled vs employed); rented housing
(aHR=1.72; 1.262.37 vs homeowner); not enough money for basic needs (aHR=1.82; 1.192.78 vs enough);
current smoking (aHR=1.39; 1.021.91 vs never); recent injection-drug use (aHR=2.11; 1.303.43); anxiety
symptoms (aHRs=1.39; 1.011.91, 2.06; 1.432.95 for mild and moderate vs none/minimal); depressive
symptoms (aHRs=1.67; 1.172.38, 1.91; 1.302.78 for moderate and severe vs none/minimal); treated/
untreated depression (aHRs=1.65; 1.032.64 for treated depression only, 1.87; 1.392.52 for depressive
symptoms only; 1.53; 1.052.24; for treated depression and depressive symptoms, versus neither). Associa-
tions were broadly similar in those with controlled HIV and high CD4.
Interpretation: Social circumstance, socioeconomic disadvantage, adverse lifestyle factors and poorer mental
health are strong predictors of hospitalisation in PLHIV, highlighting the need for targeted interventions and care.
Funding: British HIV Association (BHIVA) Research Award (2017); SMR funded by a PhD fellowship from the
Royal Free Charity.






Socioeconomic factorsLtd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Monitoring the risk and predictors of hospitalisations among peo-
ple living with HIV (PLHIV) is important, as hospitalisation is a keyindicator of serious morbidity and a significant contributor to health-
care costs [1,2].
The success of combination antiretroviral therapy (cART, a combi-
nation usually including three or more antiretroviral drugs from at
least two drug classes) resulted in dramatic reductions in mortality
and incidence of AIDS-defining illnesses among PLHIV from the mid-
1990s [3]. Over time, non-AIDS related causes began to account for
an increasing proportion of hospitalisations among PLHIV [4,5].
Research in context
Evidence before this study
We conducted a comprehensive literature search on the Ovid
MEDLINE database on 21 January 2019 and updated our search
on 29 October 2020 to identify articles investigating predictors
of hospitalisation in people living with HIV (PLHIV) in high
income countries that included at least some data from 2008
onwards. We used the following search terms to identify rele-
vant studies (including MeSH terms): (hospitalisation OR hospi-
talization OR patient admission OR inpatient OR inpatients OR
hospital discharge) AND (HIV OR HIV-1 OR HIV-2 OR human
immunodeficiency virus OR HIV infection OR Acquired Immu-
nodeficiency Syndrome) AND (predictor OR risk factor OR asso-
ciated OR association OR socio-economic OR demographic OR
gender OR immunologic* OR virologic* OR antiretroviral OR
sexual orientation OR mental health OR lifestyle). We addition-
ally searched the webpages of observational HIV cohorts for rel-
evant publications. Of all studies identified, most did not
include data beyond 2010 and were conducted in the US; the
majority focused on demographic, clinical and HV-related fac-
tors rather than social, economic, mental health and lifestyle
factors. We found no studies on predictors of hospitalisation
from the UK in the contemporary cART era (post 2010) and
only two from Europe (Italy), neither of which included socio-
economic or mental health factors.
Added value of this study
Our study is the most comprehensive analysis of predictors of
hospitalisations in PLHIV in Europe in the contemporary cART
era. It demonstrates that non-HIV related factors including
social and economic circumstance, lifestyle factors and mental
health, in addition to demographic and HIV-related factors, are
strong predictors of subsequent all cause hospitalisation.
Importantly, we found the association of socioeconomic disad-
vantage and poor mental health with subsequent hospitalisa-
tion to be at least as strong as that for smoking and alcohol
dependency, and similarly strong specifically among people
with virologically controlled HIV and high CD4 count.
Implications of all the available evidence
Our findings emphasize the need for support targeted to those
with psychosocial and economic needs and highlight the
importance of holistic care for PLHIV. Given the high costs of
hospitalisation, targeted interventions could be cost-effective.
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settings in the cART era have found that demographic factors [6]
(including older age [4,7-13], female gender [4,9,14], black or minor-
ity ethnicity [13,15]) and clinical HIV markers (including low CD4
count [4,7,9,11,13], high viral load [7,9,11,13,16], Hepatitis C or B
coinfection [4,9,17] and ART non-adherence [16]) predict hospitalisa-
tion among PLHIV. Other studies found evidence that poor mental
health was predictive of hospitalisation [8,12,14,18]; findings were
less consistent for social [11,14], socioeconomic [10,12,14,19] and
lifestyle factors [8,10,12,14,15,18,20]. Most studies of hospitalisation
among PLHIV were conducted in the US, a setting without universal
access to healthcare, and few included data beyond 2010 [4,9,14,16-
18,20]. There has been little research on the predictors of hospitalisa-
tion among PLHIV in the last decade - the era of contemporary cART -
particularly on the role of non-HIV related factors including social
and economic circumstance and mental health.This study includes a cohort of PLHIV recruited from a large Lon-
don centre in the Antiretrovirals, Sexual Transmission Risk and Atti-
tudes (ASTRA) questionnaire study in 2011 who consented to clinical
data linkage. We assess the prospective associations of question-
naire-assessed social circumstance, socioeconomic, mental health
and lifestyle factors at baseline with the subsequent rate of hospital-
isation between 2011 and 2018. We also investigate these associa-
tions specifically among individuals with virologically controlled HIV
and high CD4 count. To our knowledge, this is the first UK study to
comprehensively assess predictors of hospitalisation among PLHIV in
the current cART era.
2. Methods
The ASTRA study recruited people living with diagnosed HIV from
eight HIV outpatient clinics in England from February 2011 to
December 2012 [21]. All participants self-completed a confidential
questionnaire that included sections on demographic, social circum-
stance, socioeconomic, mental health and lifestyle factors as well as
clinical and HIV-related factors and sexual behaviour. The most
recent viral load and CD4 count at baseline for each participant was
documented from clinic records. Participants were additionally asked
whether they consented to linkage of questionnaire data with routine
clinic data. Ethical approval for the ASTRA study was obtained via the
North West London research ethics committee (reference 10/H0720/
70).
A total of 1336 patients at the Royal Free Hospital were invited to
participate in ASTRA, 899 completed questionnaires (67%); of those
809 (90% of respondents) consented to linkage and 798 had sufficient
follow-up information to be included in the present study. The study
collected information on all hospitalisations occurring among the
798 individuals that were documented in their Royal Free Hospital
medical records, covering the period from their date of questionnaire
completion (February to December 2011; baseline) until 1 June 2018.
Information on admissions to the Royal Free Hospital was obtained
from electronic records of admissions and discharges routinely
recorded in the hospital database. Information on admissions to hos-
pitals other than the Royal Free was obtained through a comprehen-
sive and detailed review of electronic and paper patient case notes,
carried out for all 798 participants. The information collected
included dates of admission and discharge, the admitting hospital,
whether the admission was classified as an emergency and the
causes of hospitalisation. The causes were classified by an HIV clini-
cian using ICD-10 codes; up to five causes could be documented for
every admission. Hospitalisations were defined as overnight stays at
the hospital; day cases were not included.
Individuals were followed from the date of questionnaire comple-
tion (baseline) until June 2018, or their death or last clinic interaction
if this occurred before June 2018. If an individual had a date of death
recorded more than one year after their last clinic visit, this last visit
was defined as the end of follow-up to reduce the risk of bias.
The main exposure variables of interest were:
Social circumstance factors: stable partner (living with partner; not
living with partner; no stable partner); having children (yes; no); dis-
closure of HIV status to at least one person who is not a healthcare
worker (yes; no); social support (1 (high) to 5 (low) based on modi-
fied version of DukeUNC Functional Social Support Questionnaire)
[22].
Socioeconomic factors: employment (employed; unemployed;
sick/disabled; retired; other); housing (homeowner; renting (council,
housing association or private); temporary/unstable/other); highest
level of education (university or above; below university; none);
financial hardship (“Do you have enough money to cover your basic
needs?” Always; mostly; sometimes; no).
Lifestyle factors: smoking (never; ex; current); recreational drug
use in past 3 months (injection drug use; non-injection use of
S.M. Rein et al. / EClinicalMedicine 31 (2021) 100665 3chemsex-associated drugs (methamphetamine; GHB/GBL; mephe-
drone); other non-injection drug use; no drug use); current alcohol
consumption(first two questions of AUDIT-C score 0; 12; 34; 56;
78)[38]; evidence of alcohol dependency (CAGE 4-item question-
naire score 0; 1; 2; 3; 4) [23].
Mental health factors: depressive symptoms on PHQ-9 (none/min-
imal (total score 04); mild (59); moderate (1014); severe
(1527)) [24]; depressive symptoms/current treatment (‘medicine or
other therapy’) for depression (PHQ-9 <10 no treatment; PHQ-9 <10
on treatment; PHQ-9  10 no treatment; PHQ-9  10 on treatment);
anxiety symptoms on GAD-7 (none/minimal (total score 04); mild
(59); moderate (1014); severe (1521)) [25].
Additional factors of interest were demographic, HIV-related, and
clinical factors: age (35; 3650; 5160; >60 years), ‘demographic
group’ (men who have sex with men (MSM); Black African heterosex-
ual men; heterosexual men of other ethnicity; Black African women;
women of other ethnicity, using Public Health England classification
of the key demographic groups of PLHIV) [26], baseline CD4 count (in
cells/ml; >800; 500800; 350499; 200349; 199); nadir CD4
count (in cells/ml; >349; 200349; 50199; <50); baseline viral
load (50 copies/ml; >50 copies/ml); years since HIV diagnosis (<5;
5-<10; 10-<20; 20); ART status (on ART; stopped ART; never taken
ART); ART non-adherence defined as having missed 2 days of ART
at a time in the past 3 months (never/don’t know; once; 23 times;
>3 times); previous Hepatitis C diagnosis. Baseline values were used
for all variables. CD4 count and VL were obtained from clinical
records; other factors were obtained from the questionnaire.
3. Statistical analysis
We calculated rates of hospitalisation overall and by exposure
categories as the number of hospitalisations divided by person-
time at risk, including repeated hospitalisation from the same
individual. We assessed the univariable and multivariable associa-
tions between each baseline factor and subsequent time toTable 1
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Viral load 50 copies/ml
Years since HIV diagnosis
Median (IQR)
<5hospitalisation using Prentice-Williams-Peterson gap time models
(PWP-GT) to calculate hazard ratios (HR) of repeated all-cause
hospitalisation. PWP models are an extension of Cox regression
models that allow for the analysis of multiple events by stratifica-
tion, based on the prior number of events [27]. For every subse-
quent event, the population at risk includes only those with a
previous event. Modelling the gap-time (the time between dis-
charge from one hospitalisation to admission for the next, or cen-
soring) ensures that the time during which the individual is still
in hospital and therefore cannot be at risk does not contribute to
the time to the next event/censoring. We used robust sandwich
covariance matrix estimators to account for within-subject corre-
lation for repeated hospitalisation. For these models, the data
were truncated after the 4th hospitalisation to avoid unstable
estimates due to small risk sets in later strata. In the multivari-
able analysis, each factor was considered separately, adjusted for
the following core factors: demographic group, age group and
time since HIV diagnosis, as defined above and shown in Table 1.
These core factors were chosen as potential confounders not
judged to be on the causal pathway between the exposures of
interest and hospitalisation.
We also assessed associations among the subset of individuals
who were on ART, with viral load 50 cells/ml and CD4 count 500
cells/ml at baseline and performed tests for interaction to investigate
whether associations differed in this subset.
We conducted complete case analyses as the number of missing
values for each variable was low (see Table 1).
We used SAS (version 9.4) for all statistical analyses and the
ggplot2 package in R (R version 3.6.3) to create figures.
4. Role of the funding source
Funding for this project was awarded through peer review. After
this, the funders played no further role in the analysis, presentation
or interpretation of study results.V) and those with controlled HIV and high CD4 count.
All PLHIV PLHIV with controlled HIV and high CD4 counta
798 (100%) 461 (100%)
46 (4051) 46 (4052)
94 (12%) 47 (10%)
471 (59%) 277 (61%)
214 (27%) 113 (25%)
19 (2.4%) 24 (5.2%)
592 (74%) 349 (76%)
29 (3.6%) 15 (3.3%)
47 (5.9%) 20 (4.3%)
65 (8.2%) 40 (8.7%)
65 (8.2%) 37 (8.0%)
621 (441820) 731 (610923)
215 (27%) 188 (41%)




189 (78277) 200 (100278)
112 (14%) 56 (12%)
267 (33%) 176 (38%)
275 (34%) 164 (36%)
144 (18%) 65 (14%)
653 (82%) 461 (100%)
11 (617) 12 (718)
163 (20%) 57 (12%)
(continued)
Table 1 (Continued)
All PLHIV PLHIV with controlled HIV and high CD4 counta
5  10 201 (25%) 132 (29%)
10 - 20 325 (41%) 209 (45%)
20 109 (14%) 63 (14%)
ART status
On ART 719 (92%) 461 (100%)
Stopped ART 14 (1.8%) 
Never ART 50 (6.4%) 
Missing=15
Time since started ART for those on ART
Median in years (IQR) 8 (414) 8 (514)
<6 months 39 (5.5%) 7 (1.6%)
6 mth - 2 years 71 (10%) 37 (8.2%)
2 - 10 years 306 (43%) 215 (48%)
10 - 15 years 184 (26%) 123 (27%)
>=15 years 115 (16%) 68 (15%)
Missing=83 Missing=11
ART non-adherence for those on ART missed >= 2 days ART at a time in the past 3 months
No / don’t know 580 (81%) 384 (83%)
Yes, once 51 (7.1%) 35 (7.6%)
Yes, 23 times 55 (7.7%) 32 (7.0%)
Yes, >3 times 31 (4.3%) 9 (2.0%)
Missing=81 Missing=1
Prior AIDS diagnosis (clinical record) 271 (34%) 163 (35%)
Disclosed HIV status 754 (95%) 436 (95%)
Missing=5 Missing=3
Ever had Hep C 133 (17%) 67 (15%)
Employment
Employed 473 (60%) 279 (62%)
Unemployed 125 (16%) 76 (17%)
Sick / disabled 102 (13%) 55 (12%)
Retired 53 (6.8%) 29 (6.4%)
Other 31 (4.0%) 14 (3.1%)
Missing=14 Missing=8
Housing status
Homeowner 310 (39%) 195 (43%)
Renting 406 (52%) 234 (51%)
Temporary / unstable / other 72 (9.1%) 28 (6.1%)
Missing=10 Missing=4
Highest level of education
University or above 394 (50%) 238 (52%)
Below university 318 (40%) 187 (41%)
No qualifications 74 (9.4%) 29 (6.4%)
Missing=12 Missing=7
Financial hardship: Money for basic needs?
Always 391 (50%) 231 (51%)
Mostly 208 (26%) 117 (26%)
Sometimes 112 (14%) 62 (14%)
No 76 (10%) 45 (9.9%)
Missing=11 Missing=6
Current stable partner
Yes, and living with partner 329 (41%) 199 (43%)
Yes, but not living with partner 120 (15%) 74 (16%)
No 345 (43%) 185 (40%)
Missing=4 Missing=3
Has Children 185 (23%) 94 (21%)
Missing=3 Missing=3
Social support score
1 (highest) 255 (32%) 150 (33%)
2 265 (33%) 155 (34%)
3 135 (17%) 85 (19%)
4 88 (11%) 45 (10%)
5 (low) 49 (6.2%) 21 (4.6%)
Missing=6 Missing=5
Smoking status
Never 281 (36%) 156 (34%)
Ex-smoker 255 (32%) 147 (32%)
Current smoker 254 (32%) 156 (34%)
Missing=8 Missing=2
Recreational drug use in past 3 months
No 434 (54%) 246 (53%)
Non-IDU, other 254 (32%) 152 (33%)
Non-IDU chemsex drugs 87 (11%) 51 (11%)
IDU 23 (2.9%) 12 (2.6%)
Alcohol dependency (CAGE score)
0 (no) 528 (67%) 311 (68%)
(continued)
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Table 1 (Continued)
All PLHIV PLHIV with controlled HIV and high CD4 counta
1 119 (15%) 72 (16%)
2 82 (10%) 41 (8.9%)
3 50 (6.3%) 27 (5.9%)
4 (strong dependency) 14 (1.8%) 9 (2.0%)
Missing=5 Missing=1
Alcohol consumption (modified AUDIT score)
0 (none) 141 (18%) 81 (18%)
12 (low) 200 (26%) 121 (27%)
34 227 (29%) 135 (30%)
56 178 (23%) 96 (21%)
78 (high) 33 (4.2%) 17 (3.8%)
Missing=19 Missing=11
Symptoms of anxiety (GAD-7 score)
04 (no anxiety) 459 (58%) 261 (57%)
59 177 (22%) 108 (23%)
1014 82 (10%) 41 (8.9%)
1521 (severe anxiety) 80 (10%) 51 (11%)
Depressive symptoms (PHQ-9 score)
04 (none/minimal) 427 (54%) 253 (55%)
59 (mild) 163 (20%) 95 (21%)
1014 (moderate) 105 (13%) 55 (12%)
>=15 (severe) 103 (13%) 58 (13%)
PHQ-9 depression and receiving treatment for depression
PHQ-9 <10, no treatment 526 (66%) 304 (66%)
PHQ-9 <10, on treatment 64 (8.0%) 44 (9.5%)
PHQ-9  10, no treatment 115 (14%) 62 (13%)
PHQ-9  10, on treatment 93 (12%) 51 (11%)
MSM=men who have sex with men; ART=antiretroviral therapy.
a on antiretroviral therapy with viral load 50 copies/ml and CD$ count 500 cells/ml.
Table 2
Hospitalisations and mortality during follow-up: All study participants during
follow-up of all study participants and those with controlled HIV and high
CD4 count.
All PLHIV (N = 798) PLHIV with controlled




6.4 (6.06.6) 6.4 (6.16.7)
Number of deaths dur-
ing follow-up
17 (2.1%) 9 (1.95%)
Hospitalisations during
follow-up
274 (100%) 100 (100%)
Emergency
hospitalisations




0 hospitalisations 645 (81%) 385 (84%)
1 hospitalisation 97 (12%) 59 (13%)
2 hospitalisations 31 (3.9%) 12 (2.6%)
3 hospitalisations 6 (0.8%) 3 (0.7%)
4 hospitalisations 8 (1.0%) 2 (0.4%)
5 hospitalisations 7 (0.9%) 0 (0%)
>5 hospitalisations 4 (0.5%) 0 (0%)
PLHIV=people living with HIV; IQR=interquartile range.
a on antiretroviral therapy with viral load 50 copies/ml and CD$ count
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Of 798 included individuals, 592 (74%), 76 (9.5%) and 130
(16%) were MSM, heterosexual men and women respectively;
median age (IQR) was 46 (4051) years (Table 1). Median follow-
up time was 6 years; there were 274 hospitalisations and 17
deaths over 4710 person-years of observation, with 153 people
(19%) being hospitalised at least once. In total, 202 (74%) hospital-
isations were emergencies (Table 2). The overall rate of hospital-
isation was 5.8/100 person-years (95% CI: 5.16.5). The rate of
re-admission among those previously hospitalised was 64.2/100
person-years (52.775.7). The median time between discharge
and re-admission in those with repeated hospitalisation was
237 days (IQR 54583). Seventeen (18%) readmissions were
within 30 days of discharge.
The most common ICD-10 classified causes of hospitalisation were
diseases of the circulatory (46; 16.8%), digestive (36; 13.1%) and
respiratory systems (32; 11.7%), infectious and parasitic diseases (30;
11.0%), injury, poisoning and other consequences of external causes
(29; 10.6%), genitourinary diseases (27; 9.9%) and neoplasms (25;
9.1%).
Rates of hospitalisation according to the exposures of interest are
shown in Fig. 1, unadjusted and adjusted hazard ratio are given in
Table 3.
5.1. Social circumstance
Rates of hospitalisation were higher among individuals with
children, those without, or not living with, a stable partner, and
those who had not disclosed their HIV status (Fig. 1). Hospitalisa-
tion rates increased with lower levels of social support. In the
PWP unadjusted analysis (Table 3), having children and having
no stable partner were significant predictors of hospitalisation,
with evidence of a trend for lower social support. There was no
association with disclosure. Patterns of association were similar
after adjustment.5.2. Socioeconomic factors
Individuals with lower socioeconomic status, including non-
employment, rented or unstable housing and financial hardship, as
well as those without educational qualifications, had higher rates of
hospitalisation. In the PWP unadjusted analysis, non-employment,
rented housing and greater financial hardship strongly predicted hos-
pitalisation, whereas education did not. Associations were similar
after adjustment, except that the elevated risk associated with being
retired was attenuated due to adjustment for age.500 cells/ml
Fig. 1. Crude rates of hospitalisation and 95% confidence intervals (CI) according to a.) social circumstance, b.) socioeconomic, c.) lifestyle and d.) mental health factors. Pyrs=person-
years.
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Table 3
Unadjusted and adjusted hazard ratios of hospitalisation according to social circumstance, socioeconomic, lifestyle and mental health factors.
Unadjusted HR (95% CI) p-value; test for trend Demographic adjusted HR (95% CI)* p-value; test for trend
Social circumstance factors
Current stable partner 0.04 0.02
Yes, and living with partner 1.0 1.0
Yes, but not living with partner 1.39 (0.92, 2.11) 1.43 (0.94, 2.17)
No 1.55 (1.10, 2.18) 1.59 (1.16, 2.20)
Has children 0.004 0.02
No 1.0 1.0
Yes 1.51 (1.14, 1.99) 1.50 (1.08, 2.10)
Social support score 0.35; 0.41;
1 (highest) 1.0 0.09 (t)** 1.0 0.11 (t)**
2 1.20 (0.87, 1.66) 1.19 (0.86, 1.66)
3 1.04 (0.70, 1.56) 1.03 (0.68, 1.55)
4 1.36 (0.93, 1.99) 1.36 (0.92, 2.01)
5 (low) 1.56 (0.96, 2.53) 1.51 (0.92, 2.46)
Disclosure of HIV status 0.19 0.28
Yes 1.0 1.0




Unemployed 1.65 (1.15, 2.36) 1.56 (1.07, 2.27)
Sick / disabled 2.48 (1.78, 3.47) 2.39 (1.70, 3.37)
Retired 1.98 (1.32, 2.98) 1.33 (0.79, 2.22)
Other 1.38 (0.73, 2.61) 1.43 (0.71, 2.85)
Housing status 0.02 0.003
Homeowner 1.0 1.0
Renting 1.60 (1.16, 2.20) 1.72 (1.26, 2.37)
Temporary / unstable / other 1.35 (0.83, 2.19) 1.46 (0.88, 2.43)
Highest level of education 0.11; 0.35;
University or above 1.0 0.30 (t)** 1.0 0.48 (t)**
Below university 0.95 (0.73, 1.24) 0.95 (0.73, 1.24)
No qualifications 1.41 (0.97, 2.06) 1.28 (0.85, 1.91)
Financial hardship: Money for 0.04; 0.04;
basic needs? 1.0 0.005 (t)** 1.0 0.005
Always 1.17 (0.85, 1.61) 1.20 (0.86, 1.67) (t)**
Mostly 1.41 (1.01, 1.97) 1.36 (0.98, 1.90)
Sometimes 1.74 (1.15, 2.63) 1.82 (1.19, 2.78)
No
Lifestyle factors
Smoking status 0.13 0.11
Never 1.0 1.0
Ex-smoker 1.08 (0.77, 1.51) 1.10 (0.79, 1.54)
Current smoker 1.35 (1.00, 1.82) 1.39 (1.02, 1.91)
Recreational drug use in past 3 months
No 1.0 0.01 1.0 0.009
(continued)
Fig. 1 Continued.
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Table 3 (Continued)
Unadjusted HR (95% CI) p-value; test for trend Demographic adjusted HR (95% CI)* p-value; test for trend
Non-IDU chemsex drugs 0.75 (0.46, 1.22) 0.98 (0.57, 1.67)
Non-IDU other 0.93 (0.70, 1.24) 0.96 (0.70, 1.31)
IDU 1.80 (1.18, 2.73) 2.11 (1.30, 3.43)
Alcohol dependency (CAGE score) 0.32; 0.36;
1.0 0.32 (t)** 1.0 0.25 (t)**
0 (no) 0.90 (0.61, 1.34) 0.95 (0.64, 1.42)
1 1.30 (0.92, 1.83) 1.34 (0.95, 1.90)
2 0.93 (0.46, 1.87) 0.97 (0.47, 1.99)
3 1.92 (0.81, 4.58) 1.62 (0.78, 3.34)
4 (strong dependency)
Alcohol consumption (modified AUDIT score) 0.03; 0.04;
0 (none) 1.0 0.89 (t)** 1.0 0.81 (t)**
12 (low) 0.62 (0.44, 0.89) 0.59 (0.41, 0.86)
34 0.77 (0.56, 1.05) 0.80 (0.56, 1.13)
56 0.77 (0.51, 1.18) 0.84 (0.54, 1.31)
78 (high) 1.24 (0.71, 2.14) 1.06 (0.63, 1.80)
Mental health factors
Anxiety symptoms (GAD-7 score) 0.002; 0.002;
04 (no anxiety) 1.0 0.002 (t)** 1.0 0.002 (t)**
59 (mild) 1.40 (1.02, 1.92) 1.39 (1.01, 1.91)
1014 (moderate) 1.98 (1.41, 2.79) 2.06 (1.43, 2.95)
>=15 (severe anxiety) 1.30 (0.87, 1.94) 1.31 (0.87, 1.98)
Depressive symptoms(PHQ-9 score) 0.007; 0.005;
04 (none/minimal) 1.0 0.0003 (t)** 1.0 0.0002 (t)**
59 (mild) 1.34 (0.92, 1.94) 1.34 (0.93, 1.95)
1014 (moderate) 1.63 (1.15, 2.31) 1.67 (1.17, 2.38)
>=15 (severe) 1.81 (1.26, 2.60) 1.91 (1.30, 2.78)
PHQ-9 depression and receiving treatment for depression 0.003 0.0004
PHQ-9 <10, no treatment 1.0 1.0
PHQ-9 <10, on treatment 1.50 (0.97, 2.37) 1.65 (1.03, 2.64)
PHQ-9  10, no treatment 1.74 (1.29, 2.34) 1.87 (1.39, 2.52)
PHQ-9  10, on treatment 1.49 (1.03, 2.16) 1.53 (1.05, 2.24)
Demographic and clinical factors
Demographic group 0.008 0.007
MSM 1.0 1.0
Black African heterosexual men 1.17 (0.71, 1.93) 1.19 (0.72, 1.96)
Other heterosexual men 1.85 (1.27, 2.68) 1.93 (1.32, 2.82)
Black African women 0.84 (0.56, 1.25) 0.90 (0.59, 1.37)
Other women 1.43 (0.95, 2.14) 1.49 (0.97, 2.30)
Age (years) 0.01; 0.005;
<=35 1.0 0.02 (t)** 1.0 0.05 (t)**
3650 1.00 (0.66, 1.52) 0.85 (0.55, 1.31)
5160 1.11 (0.70, 1.76) 0.92 (0.57, 1.50)
>60 1.76 (1.10, 2.82) 1.60 (0.97, 2.66)
CD4 count (cells/ml) <0.0001; <0.0001;
>800 1.0 <0.0001 (t)** 1.0 <0.0001 (t)**
500800 0.97 (0.70, 1.36) 0.99 (0.71, 1.37)
350499 1.54 (1.07, 2.20) 1.56 (1.09, 2.22)
200349 1.58 (1.04, 2.38) 1.45 (0.89, 2.34)
<=199 2.49 (1.70, 3.65) 2.53 (1.72, 3.74)
CD4 count nadir (cells/ml) 0.01 0.13
>349 1.0 0.003 (t)** 1.0 0.027 (t)**
200349 1.13 (0.69, 1.83) 1.05 (0.64, 1.81)
50199 1.33 (0.83, 2.13) 1.19 (0.74, 1.93)
<50 1.80 (1.13, 2.87) 1.55 (0.94, 2.57)
HIV viral load <0.0001 <0.0001
50 copies/ml 1.0 1.0
>50 copies/ml 1.73 (1.33, 2.26) 1.86 (1.41, 2.45)
Years since HIV diagnosis 0.059; 0.085;
<5 1.0 0.087 (t)** 1.0 0.04 (t)**
5-<10 0.83 (0.55, 1.25) 0.87 (0.58, 1.31)
10-<20 1.02 (0.73, 1.42) 1.14 (0.82, 1.59)
>=20 years 1.41 (0.97, 2.04) 1.47 (0.99, 2.16)
ART status 0.36 0.39
On ART 1.0 1.0
Stopped ART 1.54 (0.74, 3.21) 1.60 (0.78, 3.29)
Never ART 0.81 (0.48, 1.38) 0.90 (0.49, 1.64)
ART non-adherence missed >= 2 days ART at a time in
past 3 months
0.0004; 0.0006;
No / don’t know 1.0 0.0004 1.0 0.0004 (t)**
Yes, once 1.70 (1.09, 2.65) (t)** 1.86 (1.16, 2.99)
Yes, 23 times 1.70 (1.15, 2.50) 1.71 (1.16, 2.52)
Yes, >3 times 2.16 (1.47, 3.18) 2.00 (1.33, 3.01)
Not on ART 1.50 (1.01, 2.23) 1.62 (1.05, 2.49)
Ever had Hepatitis C 0.14 0.19
(continued)
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Table 4
Unadjusted and adjusted hazard ratios of hospitalisation according to social circumstance, socioeconomic, lifestyle and mental health factors in individuals with controlled HIV
(CD4 >=500; virally suppressed; on ART) at baseline.
Unadjusted HR (95% CI) p-value; test for trend Demographic adjusted HR (95% CI)* p-value; test for trend
Social circumstance
Current stable partner 0.30 0.31
Yes, and living with partner 1.0 1.0
Yes, but not living with partner 1.50 (0.85, 2.64) 1.49 (0.88, 2.55)
No 1.38 (0.85, 2.24) 1.28 (0.80, 2.04)
Has children 0.18 0.23
No 1.0 1.0
Yes 1.37 (0.87, 2.16) 1.50 (0.78, 2.90)
Social support score 0.31; 0.076;
1 (highest) 1.0 0.95 (t)** 1.0 0.61 (t)**
2 0.93 (0.58, 1.49) 0.82 (0.50, 1.34)
3 0.70 (0.39, 1.25) 0.55 (0.30, 1.00)
4 1.53 (0.78, 2.99) 1.35 (0.68, 2.68)
5 (low) 0.55 (0.09, 3.62) 0.43 (0.09, 2.02)
Disclosure of HIV status 0.46 0.50
Yes 1.0 1.0




Unemployed 1.43 (0.80, 2.57) 1.33 (0.75, 2.37)
Sick / disabled 2.02 (1.17, 3.49) 1.68 (0.97, 2.91)
Retired 2.49 (1.35, 4.57) 1.75 (0.80, 3.82)
Other 3.09 (1.42, 6.71) 3.14 (1.49, 6.60)
Housing status 0.22 0.063
Homeowner 1.0 1.0
Renting 1.47 (0.95, 2.26) 1.69 (1.09, 2.60)
Temporary / unstable / other 1.29 (0.48, 3.45) 1.63 (0.62, 4.29)
Highest level of education 0.88; 0.74;
University or above 1.0 0.68 1.0 0.91
Below university 1.11 (0.73, 1.69) 1.08 (0.71, 1.64)
No qualifications 1.03 (0.47, 2.27) 0.79 (0.35, 1.75)
Financial hardship: Money for basic needs? 0.13; 0.05;
Always 1.0 0.02 (t)** 1.0 0.007 (t)**
Mostly 1.37 (0.86, 2.17) 1.53 (0.95, 2.46)
Sometimes 1.57 (0.88, 2.82) 1.55 (0.85, 2.82)
No 1.96 (1.01, 3.78) 2.34 (1.23, 4.49)
Lifestyle factors
Smoking status 0.68 0.68
Never 1.0 1.0
Ex-smoker 0.97 (0.59, 1.59) 1.04 (0.64, 1.69)
Current smoker 1.18 (0.72, 1.96) 1.24 (0.74, 2.06)
Recreational drug use in past 3 months 0.23 0.19
No 1.0 1.0
Non-IDU chemsex drugs 0.98 (0.56, 1.71) 1.40 (0.73, 2.69)
Non-IDU other 1.22 (0.77, 1.93) 1.27 (0.78, 2.06)
IDU 2.00 (0.98, 4.08) 2.47 (1.09, 5.64)
Alcohol dependency (CAGE score) 0.02; 0.04;
0 (no) 1.0 0.51 (t)** 1.0 0.36 (t)**
1 0.55 (0.30, 1.03) 0.66 (0.35, 1.25)
2 1.78 (1.08, 2.93) 1.90 (1.13, 3.21)
3 0.72 (0.23, 2.25) 0.77 (0.24, 2.52)
4 (strong dependency) 1.53 (0.46, 5.10) 1.41 (0.50, 3.93)
Alcohol consumption (modified AUDIT score) 0.04; 0.25;
0 (low) 1.0 0.99 (t)** 1.0 0.84 (t)**
12 1.01 (0.55, 1.83) 0.89 (0.49, 1.64)
34 0.81 (0.44, 1.50) 0.81 (0.43, 1.51)
56 0.72 (0.36, 1.46) 0.75 (0.36, 1.54)
78 (high) 2.15 (1.04, 4.48) 1.84 (0.80, 4.23)
Mental health factors
Anxiety symptoms (GAD-7 score) 0.02; 0.02;
(continued)
Table 3 (Continued)
Unadjusted HR (95% CI) p-value; test for trend Demographic adjusted HR (95% CI)* p-value; test for trend
No /missing 1.0 1.0
Yes 1.23 (0.94, 1.62) 1.22 (0.91, 1.63)
MSM= men who have sex with men; IDU=injection drug use; ART=antiretroviral therapy; *adjusted for demographic group, age, years since HIV diagnosis; **t=test for trend. After
truncating the data after the 4th hospitalisation, a total sum of 251 hospitalisations were used in the regression model.
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Table 4 (Continued)
Unadjusted HR (95% CI) p-value; test for trend Demographic adjusted HR (95% CI)* p-value; test for trend
04 (no anxiety) 1.0 0.006 1.0 0.01 (t)**
59 (mild) 1.67 (1.03, 2.71) (t)** 1.59 (0.98, 2.58)
1014 (moderate) 2.35 (1.34, 4.13) 2.48 (1.38, 4.47)
>=15 (severe anxiety) 1.47 (0.83, 2.61) 1.47 (0.78, 2.79)
Depressive symptoms (PHQ-9 score) 0.02; 0.03;
04 (none/minimal) 1.0 0.004 (t)** 1.0 0.009 (t)**
59 (mild) 1.01 (0.54, 1.89) 0.97 (0.53, 1.79)
1014 (moderate) 1.84 (1.12, 3.03) 1.82 (1.09, 3.01)
>=15 (severe) 1.96 (1.12, 3.42) 1.91 (1.03, 3.51)
PHQ-9 depression and receiving treatment for depression 0.009 0.02
PHQ-9 <10, no treatment 1.0 1.0
PHQ-9 <10, on treatment 1.55 (0.83, 2.92) 1.48 (0.76, 2.89)
PHQ-9  10, no treatment 2.21 (1.37, 3.57) 2.04 (1.25, 3.33)
PHQ-9  10, on treatment 1.80 (0.99, 3.28) 1.96 (1.05, 3.67)
Demographic and clinical factors
Demographic group 0.17 0.066
MSM 1.0 1.0
Black African heterosexual men 0.64 (0.20, 2.12) 0.76 (0.23, 2.49)
Other heterosexual men 2.27 (1.10, 4.67) 2.78 (1.34, 5.74)
Black African women 1.08 (0.58, 2.00) 1.18 (0.63, 2.19)
Other women 0.70 (0.28, 1.75) 0.71 (0.28, 1.78)
Age (years) 0.02; 0.026;
<=35 1.0 0.03 (t)** 1.0 0.16 (t)**
3650 0.96 (0.51, 1.79) 0.66 (0.33, 1.33)
5160 1.15 (0.57, 2.31) 0.75 (0.34, 1.68)
>60 2.24 (1.12, 4.48) 1.55 (0.65, 3.68)
CD4 count nadir (cells/ml) 0.39 0.46
>349 1.0 0.15 (t)** 1.0 0.27 (t)**
200349 1.73 (0.62, 4.86) 1.68 (0.65, 4.33)
50199 2.21 (0.79, 6.16) 2.03 (0.80, 5.11)
<50 1.81 (0.61, 5.41) 1.66 (0.60, 4.60)
Years since HIV diagnosis 0.05; 0.03;
<5 1.0 0.02 (t)** 1.0 0.01 (t)**
5-<10 0.96 (0.41, 2.24) 0.90 (0.39, 2.07)
10-<20 1.55 (0.72, 3.34) 1.62 (0.73, 3.61)
>=20 years 2.21 (0.94, 5.15) 2.29 (0.93, 5.67)
ART non-adherence missed >= 2 days ART at a time in
past 3 months
0.36; 0.38;
No / don’t know 1.0 0.092 1.0 0.10 (t)**
Yes, once 1.12 (0.57, 2.20) (t)** 1.14 (0.57, 2.29)
Yes, 23 times 1.71 (0.94, 3.12) 1.70 (0.92, 3.12)
Yes, >3 times 1.35 (0.42, 4.33) 1.36 (0.40, 4.60)
Ever had Hepatitis C 0.44 0.33
No /missing 1.0 1.0
Yes 1.24 (0.72, 2.12) 1.31 (0.76, 2.26)
MSM= men who have sex with men; IDU=injection drug use; ART=antiretroviral therapy; *adjusted for demographic group, age, years since HIV diagnosis; **t=test for trend. After
truncating the data after the 4th hospitalisation, a total sum of 97 hospitalisations were used in the regression model.
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Recreational injection drug use was strongly associated with
higher hospitalisation rates and an increased hazard in the unad-
justed PWP analysis, but non-injection drug use (including non-injec-
tion chemsex drug use) was not. After adjustment, the association for
injection drug use was stronger, due to the fact that all but one injec-
tion drug user in the cohort were MSM, who had a lower rate of hos-
pitalisation than the other demographic groups. There was a J-
shaped association between level of alcohol consumption and hospi-
talisation, with the highest hazard in the group with highest con-
sumption. Alcohol dependency was not significantly associated with
hospitalisation. There was a trend for an increased hazard for current
smokers compared to non-smokers.
5.4. Mental health factors
Depressive symptoms and anxiety symptoms were strongly asso-
ciated with higher hospitalisation rates and an increased hazard in
unadjusted and adjusted PWP analyses. For the variable incorporat-
ing depressive symptoms and current treatment for depression, the
hazard was higher in all three groups with evidence of current
depression compared to those without.5.5. Demographic and clinical factors
Higher rates of hospitalisation were associated with being a het-
erosexual man or woman of ethnicity other than Black African, age
greater than sixty, lower CD4 count, CD4 nadir <50, viral non-sup-
pression, greater ART non-adherence, time since HIV diagnosis
greater than 20 years.
5.6. Associations with hospitalisations among people with controlled
HIV and high CD4 count
There were 461 participants on ART with VL<50c/mL and CD4
count >500 at baseline. One hundred hospitalisations occurred in 76
(16%) people over 2746 person-years of observation. Sixty (60%)
were emergencies, a lower proportion compared to the overall study
population. The rate of hospitalisation was 3.6/100 person-years
(95% CI: 2.94.4) and the rate of re-admission was 47.3/100 person-
years (28.066.7). For comparison, in individuals without controlled
HIV and high CD4 count, the rate of hospitalisation was 8.9/100 per-
son-years (7.510.2). In those with controlled HIV and high CD4
count the pattern of associations was broadly similar to that in the
whole cohort. In particular, in the adjusted analysis, socioeconomic
disadvantage, injection drug use, alcohol dependency and poor
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of social support and ‘no partner’ with hospitalisation appeared
weaker (Table 4). None of the tests for interaction comparing associa-
tions between those with and without virological control and high
CD4 count were significant (p>0.05 for all factors in Table 4).
6. Discussion
To our knowledge, this analysis, using linkage between question-
naire responses, routine clinic data and a detailed review of hospital
records, is the most comprehensive analysis of predictors of hospital-
isations in PLHIV in Europe in the contemporary cART era. Socioeco-
nomic disadvantage, social circumstances, evidence of mental health
disorders and adverse lifestyle factors were all predictive of subse-
quent hospitalisation, in addition to demographic and clinical factors.
Our findings emphasize the need for differentiated care and tar-
geted interventions to support socially disadvantaged groups, and to
help detect, treat and prevent mental health problems and modify
adverse lifestyle factors, to improve health outcomes in PLHIV. It is
important to note that the association of factors such as financial
hardship and poor mental health with subsequent hospitalisation
was as strong as that for smoking and alcohol dependency, and simi-
lar among people with controlled HIV and high CD4 count. As univer-
sal treatment with antivirals is now standard practice for all PLHIV in
the UK (regardless of CD4 count) these wider social and economic
determinants of health should receive increasing focus as key predic-
tors of morbidity in PLHIV.
There is little research on the impact of social support, relation-
ship and family status on the risk of hospitalisation in PLHIV. Two US
studies did not find an association between marital status and hospi-
talisation [11,14], whereas we found that not having a stable partner
and having children were associated with higher hazard of hospital-
isation in all PLHIV, with evidence for an effect of lower social sup-
port. The effect of having children was not attenuated after adjusting
for demographic group, and was similar in those with and without a
current partner (test for interaction=0.60). Those with children and
no partner were at the highest risk of hospitalisation. Furthermore,
there was an interaction between demographic group and having
children (p = 0.0492). In four of the five demographic subgroups,
those with children had a higher hospitalisation rate than those with-
out (crude rate ratios from 1.7 to 4.5), but among Black African
women, those with children had a lower rate (rate ratio=0.42).
The higher risk among PLHIV with children may be explained by
competing responsibilities, increased stress or greater financial or
time pressures, which take a parent’s emphasis away from maintain-
ing their own health. On the other hand, those living with a partner
were at lower risk of hospitalisation, which is consistent with lower
rates observed among those with high levels of social support. The
mechanisms by which social support could protect against hospital-
isation are complex, and may include protecting against depression,
having greater emotional or financial resources to cope with difficul-
ties, reducing stigma, increasing healthcare-seeking behaviour and
maintaining engagement in health and wellbeing. There was no clear
evidence for an effect of non-disclosure on hospitalisation; this is
consistent with previous analyses of the whole ASTRA study popula-
tion that found no difference according to overall non-disclosure in
prevalence of depression, ART non-adherence and virological non-
suppression [28]. Our results highlight the importance of social cir-
cumstance in determining health outcomes. Patients caring for chil-
dren and those with limited support networks may benefit from
additional services and interventions, e.g. family and childcare sup-
port, peer support, counselling, or specific health interventions.
Our findings show that markers of current socioeconomic disad-
vantage (non-employment, less secure housing situation and finan-
cial hardship) were strong predictors of hospitalisation among PLHIV,
whereas level of education was not significantly associated. Two USstudies from 2012 and 2014 found that being employed was associ-
ated with a reduced hospitalisation rate [14,19], while two other
studies found no association with monthly income, [10,12] and
results relating to education were inconsistent in PLHIV
[10,12,14,19]. A US study found an association between unstable
housing or homelessness and increased rate of hospitalisation in
PLHIV [29]. To our knowledge, there are no recent European studies
investigating the association of socioeconomic factors with hospital-
isation.
Previous results from ASTRA showed the marked associations of
socioeconomic factors with non-adherence to antiretrovirals and
viral non-suppression [30]. The present results demonstrate similarly
strong associations with a wider measure of morbidity.
The mechanisms by which lack of financial resources and other
socioeconomic disadvantages lead to increased hospitalisation are
likely to be complex and may include competing pressures and
responsibilities other than personal health, delaying seeking health
care, as well as the strong link with depression [31] and higher preva-
lence of adverse lifestyle factors. There may also be differential vul-
nerability and susceptibility to mediators such as depression, i.e. the
effect of depression on health outcomes may be stronger in groups
with socioeconomic disadvantage, implying the presence of interac-
tion [32]. It was beyond the scope of our study to investigate the spe-
cific causal pathways behind the associations of socioeconomic
factors with hospitalisation. To examine the possibility of the associa-
tions being driven by injection drug use as a contributor to inequal-
ities, we repeated the unadjusted analysis for socioeconomic factors
after excluding individuals who injected drugs at baseline. We found
that the associations were similar to the main analysis and, therefore,
that injection drug use does not appear to drive the associations
(Appendix). Our results among PLHIV parallel those in the general
population, emphasising the importance of socioeconomic disadvan-
tage as a critical determinant of health outcomes and the need for
interventions to mitigate this effect.
There was a strong association of recent injection drug use with
hospitalisation. US studies found that use of illicit drugs such as opi-
ates, crack, cocaine and heroin are associated with hospitalisation in
PLHIV [10,12,13,18,20]. Although we did not ask about specific injec-
tion drugs in our study, we did ask about drug type for drug use in
general. A number of drugs were much more commonly reported in
injection drug users compared to non-injection drug users, these
included chemsex drugs (methamphetamine, GHB/GBL, mephe-
drone) as well as opiates, crack, cocaine and anabolic steroids. Injec-
tion drug users were a small proportion of all drug users, but at much
higher risk of hospitalisation. There has been concern about the per-
ceived increase in injection of chemsex drugs (‘slamming’) in the UK;
further research on the health effects is needed. There were weak,
non-significant, associations of hospitalisation with smoking,
which was found to be associated in other studies [15,18]. We
found a J-shaped association with alcohol consumption, with
higher rates of hospitalisation in non-drinkers, and more so in
heavy drinkers, compared to low or intermediate drinking levels.
This appears consistent with literature on alcohol as a risk factor
for mortality [33]. Most other studies in PLHIV have examined
binary alcohol classifications; three found an association between
hazardous alcohol consumption and hospitalisation [8,15,20],
while four did not [10,12,14,18].
Smoking and high levels of alcohol consumption or dependency
would be expected to impact on hospitalisations due to known asso-
ciations with a range of common chronic diseases, including cancer,
respiratory and heart diseases. We would also expect an association
of alcohol abuse and chronic Hepatitis C with risk of liver related
complications in the longer term that may increase hospitalisation
risk. The associations for injection drug use and alcohol were of a
greater magnitude in those with controlled HIV and high CD4 count,
suggesting lifestyle factors may become even stronger predictors of
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related to uncontrolled HIV.
In our analysis, depression (including symptoms and currently
treated depression) and anxiety symptoms were strong predictors of
hospitalisation in PLHIV, at least as much so in those with controlled
HIV. Our findings are consistent with previous studies from the US
that investigated the impact of depression [8,12,18] and anxiety
[8,14] and other mental health problems [16] on hospitalisation in
PLHIV. Depression may be a key mediator through which social and
socioeconomic factors impact on hospital admissions, for example
through the effect of poor mental health on physical health and
health seeking behaviours, lower adherence to ART and other treat-
ments, co-existing physical illness, and in part through admissions
directly due to mental health. PLHIV with treated depression but
without symptoms according to PHQ-9 also had a higher hazard of
hospitalisation than people without evidence of depression, perhaps
because treated depression may indicate more severe mental health
problems. Co-morbidities among those with depression, and perhaps
the treatment itself, may also have adverse effects on health and
wellbeing. The findings highlight the need for regular routine assess-
ment of mental health among PLHIV and for adequate mental health
support and treatment.
As reported in a previous study at this London centre [6], we
found that women and heterosexual men of ethnicity other than
Black African were at higher risk of hospitalisation compared to
MSM. We also found an increased hazard of hospitalisation in indi-
viduals over the age of 60, with little variation in risk across the youn-
ger age groups. Other studies had similar findings, most of which
were reporting an increased risk in the oldest age groups only [7-
9,17], reflecting trends in the general population. Of several studies
that did not find an association most considered age as a continuous
rather than categorical variable and therefore potentially missed an
elevated risk in the oldest age groups [10-12,14].
Our results confirm the importance of HIV surrogate markers such
as low CD4 count and viral non-suppression, and self-reported ART
non-adherence, in predicting hospitalisation. There was also evi-
dence for an effect of longer time since HIV diagnosis (particularly
>20 years), which may reflect an adverse effect on health of longer
time with uncontrolled HIV as well as the impact of being diagnosed
in the period before effective ART. We previously reported strong
associations between longer time since HIV diagnosis and higher
prevalence of physical symptom distress, mental health problems
and functional problems, independently of age [34]. Other studies
reported some evidence of the opposite association: a negative rela-
tionship between time since HIV diagnosis and hospitalisation, [7,11]
although a high risk among newly diagnosed individuals may con-
tribute to this [6]. Hepatitis C co-infection has previously been found
to predict hospitalisation [9,17].
In our study, hospitalisations occurring outside of the Royal Free
Hospital may have been missed if not reported to the HIV physician
by the patient, general practitioner or other hospital, or if this infor-
mation was not documented. Thus, we may have underestimated the
true rate of hospitalisation, although this may be expected to impact
less on associations. We studied baseline predictors of hospitalisa-
tions over a 6- 7-year follow-up period. This may underestimate
associations for factors likely to change over time such as HIV-related
clinical factors, adverse lifestyle factors and mental health symptoms.
The rate of hospitalisation of 5.8/100 person-years in our study popu-
lation was lower than in some other recent studies in other high
income settings [13,35-37]. Our study population had a high median
CD4 count (621 cells/ml) and included a low proportion of individuals
with recent diagnosis (3.6% of individuals were within their first year
after diagnosis at baseline) for whom hospitalisation rates areparticularly high [6]. Our data are from a high-income setting, and so
are not generalizable to resource-limited settings.
In summary, in addition to clinical and demographic factors, social
circumstance, socioeconomic, lifestyle and mental health factors are
important predictors of hospitalisation in PLHIV in the UK in the
modern ART era and will likely remain key determinants of health in
the future. This highlights the importance of holistic care for PLHIV
and targeted support for those with psychosocial and economic
needs. A more detailed understanding of causal mechanisms and of
the direct and indirect effects of these factors on hospitalisation is
needed to inform possible interventions. Given the high costs of hos-
pitalisation such interventions could be cost-effective.
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Appendix 1. Distribution of hospitalisations according to exposure/stratification variables. PLHIV=people living with HIVAll PLHIV (N = 798) PLHIV with controlled HIV and high CD4 count (N = 461)
Total number of events (N = 274);
person-years (total=4710)Events used in models
after truncation after
4th event (N = 251);
gap time (total=4683)Total number of events (N = 100);
person-years (total=2746)Events used in models
after truncation after
4th event (N = 97);
gap time (total=2746)Social circumstance
Current stable partner
Yes, and living with partner 67; 1931 64; 1929 31; 1184 31; 1183
Yes, but not living with partner 46; 712 42; 707 23; 444 21; 444
No 160; 2049 144; 2028 46; 1104 45; 1.106
Has children
No 174; 3613 160; 3599 73; 2179 70; 2179
Yes 98; 1087 89; 1074 25; 558 25; 557
Social support score
1 (highest) 64; 1515 64; 1505 32; 904 32; 900
2 97; 1574 84; 1563 33; 926 31; 925
3 49; 793 42; 793 15; 496 14; 501
4 37; 507 34; 503 16; 268 16; 267
5 (low) 25; 283 24; 280 2; 122 2; 122
Disclosure of HIV status
Yes 251; 4442 229; 4416 97; 2592 94; 2592
No 22; 237 21; 235 3; 135 3; 135
Socioeconomic factors
Employment
Employed 101; 2820 92; 2821 46; 1691 43; 1695
Unemployed 46; 729 44; 725 16; 454 16; 453
Sick / disabled 83; 609 72; 588 20; 329 20; 325
Retired 31; 323 30; 319 12; 172 12; 172
Other 8; 152 8; 152 5; 57 5; 56
Housing status
Homeowner 73; 1878 63; 1878 35; 1182 32; 1186
Renting 176; 2373 162; 2352 58; 1378 58; 1374
Temporary / unstable / other 20; 407 20; 400 6; 168 6; 167
Highest level of education
University or above 131; 2317 120; 2304 49; 1412 48; 1415
Below university 99; 1908 93; 1898 45; 1136 43; 1133
No qualifications 39; 419 33; 415 5; 160 5; 160
Financial hardship: Money for basic needs?
Always 110; 2364 97; 2352 42; 1414 39; 1415
Mostly 65; 1206 63; 1200 25; 687 25; 687
Sometimes 47; 633 46; 631 16; 358 16; 358
No 46; 448 39; 441 15; 257 15; 256
Lifestyle factors
Smoking status
Never 81; 1695 76; 1688 34; 960 37; 911
Ex-smoker 78; 1484 70; 1468 28; 866 28; 863
Current smoker 108; 1485 99; 1481 38; 907 32; 960
Recreational drug use in past 3 months
No 151; 2565 141; 2544 47; 1465 45; 1465
Non-IDU chemsex drugs 19; 495 18; 491 9; 289 9; 286
Non-IDU other 79; 1518 76; 1521 40; 926 39; 929
IDU 25; 132 16; 126 4; 67 4; 66
Alcohol dependency (CAGE score)
0 (no) 166; 3112 157; 3097 67; 1844 65; 1842
1 43; 722 35; 723 11; 441 10; 446
2 37; 479 34; 473 16; 240 16; 237
3 13; 288 13; 288 4; 167 4; 167
4 (strong dependency) 9; 79 7; 71 2; 47 2; 47
Alcohol consumption (modified AUDIT score)
0 (none) 65; 808 59; 797 17; 465 17; 464
12 (low) 43; 1190 43; 1189 28; 728 28; 727
34 81; 1363 75; 1351 25; 819 25; 818
56 57; 1055 50; 1055 20; 577 17; 582
78 (high) 17; 186 14; 183 8; 100 8; 97
Mental health
Anxiety symptoms (GAD-7 score)
04 (no anxiety) 115; 2722 107; 2708 43; 1559 40; 1561
59 (mild) 76; 1039 69; 1033 30; 652 30; 651
1014 (moderate) 54; 488 49; 484 16; 240 16; 239
>=15 (severe anxiety) 29; 461 26; 457 11; 295 11; 295
Depressive symptoms (PHQ-9 score)
04 (none/minimal) 95; 2533 91; 2525 40; 1514 40; 1511
59 (mild) 68; 945 58; 936 20; 564 17; 568(continued)
(
14 S.M. Rein et al. / EClinicalMedicine 31 (2021) 100665Continued)All PLHIV (N = 798) PLHIV with controlled HIV and high CD4 count (N = 461)
Total number of events (N = 274);
person-years (total=4710)Events used in models
after truncation after
4th event (N = 251);
gap time (total=4683)Total number of events (N = 100);
person-years (total=2746)Events used in models
after truncation after
4th event (N = 97);
gap time (total=2746)1014 (moderate) 56; 646 51; 641 20; 342 20; 342
>=15 (severe) 55; 586 51; 581 20; 326 20; 326
PHQ-9 depression and receiving
treatment for depression
PHQ-9 <10, no treatment 138; 3114 125; 3099 49; 1808 46; 1809
PHQ-9 <10, on treatment 25; 364 24; 362 11; 270 11; 270
PHQ-9  10, no treatment 68; 685 64; 680 25; 370 25; 370
PHQ-9  10, on treatment 43; 547 38; 542 15; 298 15; 298
Demographic and clinical factors
Demographic group
MSM 175; 3495 161; 3481 74; 2073 71; 2074
Black African heterosexual men 14; 175 13; 171 2; 92 2; 92
Other heterosexual men 38; 287 35; 285 11; 125 11; 124
Black African women 14; 367 14; 366 8; 228 8; 228
Other women 33; 387 28; 380 5; 228 5; 228
Age
<=35 27; 529 25; 526 8; 267 8; 267
3650 143; 2798 131; 2780 51; 1673 51; 1669
5160 71; 1094 63; 1090 29; 661 26; 665
>60 33; 289 32; 287 12; 145 12; 145
CD4 count (cells/ml)  
>800 56; 1285 54; 1282
500800 79; 1942 76; 1944
350499 74; 917 66; 904
200349 41; 399 33; 397
<=199 24; 166 22; 156
CD4 count nadir (cells/ml)
>349 22; 627 22; 626 5; 295 5; 295
200349 71; 1597 68; 1591 34; 1070 34; 1066
50199 103; 1615 88; 1608 45; 986 44; 991
<50 78; 872 73; 858 16; 396 14; 395
HIV viral suppression (50 copies/ml)  -
Yes 189; 3866 172; 3849
No 85; 845 79; 833
Years since HIV diagnosis
<5 49; 930 48; 922 7; 321 7; 321
5-<10 53; 1182 45; 1174 17; 781 17; 781
10-<20 118; 1954 106; 1943 55; 1276 52; 1277
>=20 years 54; 645 52; 643 21; 368 21; 367
ART status  
On ART 237; 4255 217; 4233
Stopped ART 7; 66 6; 66
Never ART 12; 293 12; 292
ART non-adherence missed >= 2 days
ART at a time in past 3 months
No / don’t know 150; 3463 145; 3452 79; 2297 76; 2298
Yes, once 31; 286 22; 280 7; 199 7; 198
Yes, 23 times 28; 319 26; 318 12; 193 12; 193
Yes, >3 times 28; 175 24; 170 2; 52 2; 52
Not on ART/missing 37; 467 34; 462 0; 6.0 0; 6.0
Ever had Hepatitis C
No /missing 212; 3940 198; 3920 83; 2351 80; 2352
Yes 62; 770 53; 763 17; 395 17; 394
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assess social support; alcohol dependency/consumption; depressive
and anxiety symptoms
Modified Duke-UNC Functional Social Support Questionnaire
“Here is a list of some things that other people do for us that may
be helpful or supportive. Please read each statement carefully and
place a tick in the column that is closest to your situation. Give only
one answer for each row.”
Five statements (I have people who care what happens to me; I
get love and affection; I get chances to talk to someone I trust about
my personal problems; I get invitations to go out and do things with
other people; I get help when I am sick in bed) to respond to on a
scale from 1 to 5 (1=Much less than I would like; 2=Less than I would
like; 3=Some, but would like more; 4=Almost as much as I would
like; 5=As much as I would like); responses are summed to form the
overall score from 5 to 25: 1= score 25 (Highest possible); 2 = 2024;
3 = 1519; 4 = 1014; 5 = 59 (Low).
Alcohol dependency based on CAGE 4-item questionnaire
CAGE 4-item questionnaire: “Have you ever felt you should cut
down on your drinking?”; “Have people annoyed you by criticising
your drinking?”; “Have you ever felt bad or guilty about your drink-
ing?”; “Have you ever had a drink first thing in the morning to steady
your nerves or get rid of a hangover?”
Respondents reply “yes (1)” or “no (0)” to each question and num-
bers are summed to form the score from 0 to 4 (no evidence of
dependency to strong evidence of dependency).
Alcohol consumption based on first two questions from WHO
AUDIT-C score
Modified AUDIT-C score derived from first two variables of
AUDIT-C questionnaire: “How often do you have a drink containing
alcohol?”; “How many units do you drink on a typical day when you
are drinking?”. Categories are: 0 (non-drinker); 12 (1 or 2 drinks 2-
4 times per month or less; 3 or 4 drinks monthly or less); 34 (1 or 2
drinks at least twice a week; 3 or 4 drinks 2-4 times per month or 2-
3 times per week; 5 or 6 drinks 2-4 times per month or less; 7-9
drinks monthly or less); 56 (3 or 4 drinks 4 or more times a week; 5
or 6 drinks at least 2 to 3 times a week; 7-9 drinks 2-4 times per
month or 2-3 times per week; 10+ drinks 2-4 times per month or
less); 78 (7-9 drinks 4 or more times a week; 10+ drinks at least 2-
3 times per week).
Symptoms of anxiety according to Generalised Anxiety Disor-
der Assessment (GAD-7 score)
‘Over the past 2 weeks, how often have you been bothered by any
of the following problems?’
1 Feeling nervous, anxious or on edge.
2 Not being able to stop or control worrying.
3 Worrying too much about different things.
4 Becoming easily annoyed or irritated.
5 Trouble relaxing.
6 Being so restless that it is hard to sit still.
7 Feeling afraid as if something awful might happen.
Response options: Not at all (coded as 0); Several days (coded as
1); More than half the days (coded as 2); Nearly every day (coded as
3).
Numbers are summed to form the score from 0 to 21 (none/mini-
mal (total score 04); mild (59); moderate (1014); severe
(1521).
Symptoms of depression according to the Patient Health Ques-
tionnaire 9-tem scale (PHQ-9 score)
Over the past 2 weeks, how often have you been bothered by any
of the following problems?’
1 Little interest or pleasure in doing things.
2 Feeling down, depressed or hopeless.3 Trouble falling or staying asleep, or sleeping too much.
4 Feeling tired or having little energy.
5 Poor appetite or overeating.
6 Feeling bad about yourself  or that you are a failure or have let
yourself or your family down.
7 Trouble concentrating on things, such as reading the newspaper
or watching television.
8 Moving or speaking so slowly that other people could have
noticed/being so restless that it is hard to sit still.
9 Thoughts that you would be better off dead or of hurting yourself
in some way.
Response options: Not at all (coded as 0); Several days (coded as
1); More than half the days (coded as 2); Nearly every day (coded as
3).
Numbers are summed to form the score from 0 to 27 (none/mini-
mal (total score 04); mild (59); moderate (1014); severe
(1527).
Appendix 3. Unadjusted hazard ratios (HRs) for socioeconomic
factors in the complete study population after excluding individuals
who injected drugs at baseline (n = 23) (HRs (95% CI):
Employment (vs. employed): unemployed: 1.71 (1.17, 2.50), sick/
disabled: 2.66 (1.89, 3.75), retired: 2.15 (1.43, 3.25), other: 1.47 (0.78.
2.80);
Housing (vs. homeowner): renting: 1.79 (1.28, 2.51), temporary /
unstable / other: 1.48 (0.89, 2.47);
Education (vs. university or above): below university: 0.96 (0.73,
1.26); no qualifications: 1.47 (1.01, 2.15);
Money for basic needs (vs. always): mostly: 1.25 (0.90, 1.73);
sometimes: 1.46 (1.03, 2.07); never: 1.72 (1.12, 2.66)).
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